JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Выпуски журналов
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-39-41
Yu.A. Kaidash1, E.L.Shaidiyarova 1, I.A. Baryshnikov1, P.V. Sychev1,
E.V. Mayakova1, A.V. Belostotsky1, Yu.D. Udalov 2
First Experience in Treatment of Papillary Thyroid Cancer
with Metastatic Lung Infection in a 12-year-old Patient (Clinical Case)
1 Federal Scientific Clinical Center for Medical Radiology and Oncology, Dimitrovgrad, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Yulia Aleksandrovna Kaidash, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To demonstrate the successful experience of using systemic radioiodine therapy in the treatment of thyroid cancer in children.
Material and methods: In the FSBI FSCCRO of FMBA of Russia, as part of the implementation of the State assignment of FMBA of Russia, the development of a modern tool for epidemiological analysis of the results of the use of 131I radionuclide therapy in the treatment of thyroid cancer in the system of FMBA of Russia is carried out. Over 2.5 years of studies, data on the carrying out of radioiodine therapy for thyroid cancer in the nuclear medicine centers of the FMBA institutions of Russia have been studied on more than 1500 patients from different parts of the Russian Federation. The necessary medical documentation and clinical and anamnestic data of patients who underwent radioiodine therapy have been studied, and information has been collected and analyzed epidemiologically, and entered into an electronic database of patients of different age groups. However, in our database clinical cases of children’s treatment are quite rare.
Results: Due to the lack of an evidence based on prospective and retrospective studies with a large sample of pediatric patients, a significant portion of the treatment concepts for differentiated thyroid cancer in children are derived from the experience of treating adult patients. However, the more aggressive course of the disease in children, coupled with a good overall prognosis and a long life expectancy, during which adverse effects of radioiodine therapy may occur, requires a personalized approach, as demonstrated in our clinical case.
Conclusion: Based on the above, it is evident that it is necessary to develop special recommendations for the treatment and monitoring of pediatric patients with thyroid neoplasms.
Keywords: thyroid cancer, childhood, radioiodine therapy, 131I
For citation: Kaidash YuA, Shaidiyarova EL, Baryshnikov IA, Sychev PV, Mayakova EV, Belostotsky AV, Udalov YuD. The first experience of papillary thyroid cancer treatment with metastatic lung lesions in a 12-year-old patient (Clinical Case). Medical Radiology and Radiation Safety. 2026;71(1):39–41. (In Russian). DOI:10.33266/1024-6177-2026-71-1-39-41
References
1. Differentsirovannyy Rak Shchitovidnoy Zhelezy = Differentiated Thyroid Cancer. Clinical Guidelines. Moscow, Ministry of Health of the Russian Federation Publ., 2020. 56 p. (In Russ.).
2. Durnov L.A., Goldobenko G.V. Detskaya Onkologiya = Pediatric Oncology. Textbook. Moscow, Meditsina Publ., 2002. 607 p. (In Russ.).
3. Paches A.I. Opukholi Golovy i Shei = Head and Neck Tumors. Clinical Guidelines. Moscow, Prakticheskaya Meditsina Publ., 2013. P. 454-473 (In Russ.).
4. Detskaya Onkologiya = Pediatric Oncology. National Guidelines. Ed. Aliyev M.D., Polyakov V.G., Mentkevich G.L., Mayakova S.A. Moscow, Prakticheskaya Meditsina Publ., 2012. 684 (In Russ.).
5. Rumyantsev P.O., Il’in A.A., Rumyantseva U.V., Sayenko V.A. Rak Shchitovidnoy Zhelezy. Sovremennyye Podkhody k Diagnostike i Lecheniyu = Thyroid Cancer. Modern Approaches to Diagnostics and Treatment. Moscow, GEOTAR-Media Publ., 2009. 448 p. (In Russ.).
6. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Sherman S.I., Tuttle R.M. American Thyroid Association Guidelines Taskforce: Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2006 Feb;16;2:109-42. Doi: 10.1089/thy.2006.16.109. PMID: 16420177.
7. Mhiri A., Elbez I., Slim I., Ben Slimène M.F. Differentiated Thyroid Cancer in Children: The Contribution of Radioiodine Therapy. Thyroid Disorders Ther. 2015;4:171. Doi: 10.4172/2167-7948.1000171.
8. Sychev P.V., Udalov Yu.D., Mayakova Ye.V., Shcherbakov M.I., Kaydash Yu.A., Kadyrova A.M. RADIOR-25. Certificate of State Registration of the Database No. 2024625254 Russian Federation. No. 2024625013. Declared 07.11.2024. Published 18.11.2024. Applicant FNKTsRIO FMBA of Russia (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was performed within the framework of the state assignment of the FMBA of Russia registration number R&D 1022060300090-7-3.2.21.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-42-48
A.A. Labushkina, T.A. Astrelina, Yu.D. Udalov, G.E. Kodina
Relevant Questions and the Contradictions of Current Requirements to the Instructions for Medical Use of Radiopharmaceutical Drugs
A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Anna A. Labushkina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Contents
Introduction
Comparative analysis of regulatory requirements for instructions for medical use of radiopharmaceutical drugs
Additions to the requirements for Summary of Product Characteristics and Package leaflet of radiopharmaceutical drugs
Packaging of radiopharmaceutical drug products with information for healthcare professionals
Packaging of radiopharmaceutical drug products with package leaflets
Conclusion
Keywords: radiopharmaceutical drugs, regulatory requirements, summary of product characteristics, prescribing information, pa-
ckage leaflet, medication guides
For citation: Labushkina AA, Astrelina TA, Udalov YuD, Kodina GE. Relevant Questions and the Contradictions of Current Requirements to the Instructions for Medical Use of Radiopharmaceutical Drugs. Medical Radiology and Radiation Safety. 2026;71(1):42–48.
(In Russian). DOI:10.33266/1024-6177-2026-71-1-42-48
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-57-66
W.Yu. Ussov1, S.M. Minin1, Zh.Zh. Anashbaev1, E.A. Samoilova1, S.I. Sazonova2,
A.V. Grishkov1, K.N. Sorokina3, A.P. Borisenko1, Yu.B. Lishmanov4,
A.M. Chernyavsky1
Assessment of Adenosin Blood Flow Reactivity of the Primary Tumor and Metastases of Non-Small Cell Lung Cancer using Single-Photon Emission Computed Tomography of the Chest with 99mTc-MIBI
1 E.N. Meshalkin National Research Medical Center, Novosibirsk, Russia
2 Scientific Research Institute of Cardiology, Tomsk, Russia
3 National Research Novosibirsk State University, Novosibirsk, Russia
4 National Research Tomsk Polytechnic University, Tomsk, Russia
Contact person: Wladimir Yuryevich Ussov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Background: Functional pharmacological methods of influencing the tumor blood flow in lung cancer, in combination with SPECT/CT of the chest organs with 99mTc-MIBI, are completely insufficiently used today. An answer has not been received to an almost very important question: which SPECT/CT study gives the best image of lungcancer (LC) – at rest, or with a pharmacological loading test, primarily with the most widely used drug, ATP?
Purpose: Was to evaluate whether conducting a pharmacological test with ATP improves the imaging picture of lung cancer in SPECT/CT with 99mTc-MIBI. We also analyzed the relationship between the level of blood flow in the primary node of the LC and the presence of distant metastases in these individuals.
Material and methods: The examinations were conducted with the patients’ written consent. The present study included 11 patients who were initially referred for functional SPECT/CT of myocardial blood flow with 99mTc-MIBI to confirm the diagnosis of coronary artery disease. They all had lung cancer – peripheral in six and central in five. The patients were divided into two groups: group 1 (n = 5) included patients with stage T1–2N0–1M0, and group 2 (n = 6) included patients with stage T2–3N2–3M0–1 RL.
SPECT/CT with 99mTc-MIBI was performed twice in all patients – initially with a pharmacological loading functional test with intravenous ATP injection, at a dosage 0,16 mg/kgBW/min for 5 min, and then at rest, into a 64×64 matrix with a 180° rotation of each detector of a two-detector gamma camera, 32–64 projections, and a rotation radius of 35–40 cm, with a set of less than 50,000 scintillations per each. Up to 50 transverse tomographic sections of the heart and chest were reconstructed, taking into account the tissue absorption of 0.12 cm‒1. Visual analysis was performed for the pre
sence of nodular pathological neoplasms in the lungs with a pathological accumulation of 99mTc-MIBI and calculation of the values of myocardial and tumor blood flow, as TBF = SUVTc-MIBI × (MV / Bodyweight) × 100, where SUVTc-MIBI is the standardized value of radiopharmaceutical uptake, MV – the minute volume of cardiac output, in ml/min, and 100 is the conversion factor for representing the result in the usual units of ml/min/100 g of tissue.
Results: In group 1(T1–2N0–1M0) The resting tumor blood flow was 24 ± 7 ml/min/100 g of tissue, and in the case of an ATP test it was 26 ± 7 ml/min/100 g of tissue. In group 2 (T2–3N2–3M0–1, n=6), 32 ± 8 and 33 ± 7 ml/min/100 g of tissue, respectively. The best visualization of lymph nodes in SPECT/CT with 99mTc-MIBI was also achieved at rest. In patients without distant metastases (i.e. M0, these are all patients from group 1 and one from group 2, six in total) the average TBF in the tumor in all was < 28 ml/min/100 g, whereas in the presence of distant metastases (M1), the average TBF in the primary node of the RL was ≥ 27 ml/min/100 g. The increase in TBF – obviously as a manifestation of more intense tumor neoangiogenesis was accompanied by a significantly higher probability of the formation of distant RL metastases.
Conclusion: It is most optimal and informative to study the blood flow of lung cancer by SPECT/CT with 99mTc-MIBI at rest, rather than with a pharmacological test with ATP. Its greatest information content at rest regarding the visualization of affected and accumulating 99mTc-MIBI lymph nodes allows this method to be used most widely and safely in patients with suspected or verified lung cancer.
Keywords: SPECT/CT, 99mTc-MIBI, coronary heart disease, lung cancer, adenosine test, cardiooncology
For citation: Ussov WYu, Minin SM, Anashbaev ZhZh, Samoilova EA, Sazonova SI, Grishkov AV, Sorokina KN, Borisenko AP, Lishmanov YuB, Chernyavsky AM. Assessment of Adenosin Blood Flow Reactivity of the Primary Tumor and Metastases of Non-Small Cell Lung Cancer using Single-Photon Emission Computed Tomography of the Chest with 99mTc-MIBI. Medical Radiology and Radiation Safety. 2026;71(1):57–66. (In Russian). DOI:10.33266/1024-6177-2026-71-1-57-66
References
1. Merabishvili V.M., Yurkova Yu.P., Levchenko Ye.V., Shcherbakov A.M., Krotov N.F. The State of Oncological Care in Russia: Lung Cancer, Patient Survival (Population-Based Study at the Federal District Level). Voprosy Onkologii = Problems in Oncology. 2021;67;4:492-500 (In Russ.). Doi: 10.37469/0507-3758-2021-67-4-492-500. EDN AMQMYT.
2. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016 Jul;25;3:439-45. Doi: 10.1016/j.soc.2016.02.001. PMID: 27261907.
3. Novikova S.V., Vazhenin A.V., Tyukov Yu.A. Lung Cancer: Epidemiology, Diagnostics and Prevention. Nepreryvnoye Meditsinskoye Obrazovaniye i Nauka = Continuous Medical Education and Science. 2024;19;4:22–27 (In Russ.). EDN EGSBRV.
4. Minin S.M., Vasil’tseva O.Ya., Bukhovets I.L., Anashbayev Zh.Zh., Lishmanov Yu.B., Ivanovskaya Ye.A., Usov V.Yu., Chernyavskiy A.M. Pharmacological Test with Nitroglycerin in Combination with Perfusion Single-Photon Emission Computed Tomography with 99mTc-Technetrile in Assessing the Viability of Ischemic Myocardium in Patients after Acute Myocardial Infarction. Regionarnaya Gemodinamika i Mikrotsirkulyatsiya = Regional Blood Circulation and Microcirculation. 2024;23;1:50–63 (In Russ.). Doi: 10.24884/1682-6655-2024-23-1-50-6.
5. Minin S.M., Anashbayev ZH.ZH., Samoylova Ye.A., Zheravin A.A., Usov V.YU., Krasil’nikov S.Ye., Chernyavskiy A.M. SPECT/CT with 99mTc-Technetrile in Staging, Planning of External Beam Radiation Therapy and Subsequent Observation of Lung Cancer: a Clinical Case and a Targeted Literature Review. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 1996;41;6:11-15
(In Russ.). EDN MOVAXT.
6. Arsen’yev A.I., Barchuk A.A., Kostitsyn K.A., Nefedova A.V., Barchuk A.S., Chernaya A.V., Levchenko Ye.V., Tarkov S.A., Nefedov A.O., Gagua K.Ye. Panel Study of the Effectiveness of Low-Dose Computed Tomography and Transthoracic Core Biopsy in the Early Diagnosis of Lung Cancer. Vestnik Khirurgii im. I.I.Grekova = Grekov’s Bulletin of Surgery. 2018;177;1:60-64 (In Russ.). Doi: 10.24884/0042-4625-2018-177-1-60-64. EDN YWEIEK.
7. Stukanov S.L., Usov V.Yu., Kolomiyets S.A., Ryannel’ Yu.Ye., Velichko S.A., Zyryanov B.N. Single-Photon Emission Computed Tomography with 99mTc-Technetrile in Lung Cancer. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 1996;41;6:11-15 (In Russ.). EDN MOVAXT.
8. Zyryanov B.N., Siyanov V.S., Velichko S.A., Makarkin N.A. Rak Logkogo. Novyye Podkhody v Diagnostike i Lechenii = Lung Cancer. New Approaches to Diagnostics and Treatment. Tomsk, Nauchno-Isledovatel’skiy Institut Onkologii. Natsional’nyy Issledovatel’skiy Tomskiy Gosudarstvennyy Universitet Publ., 1997. 346 p. (In Russ.). ISBN 978-5-93856-283-7. EDN VFDVIL.
9. Ansheles A.A., Sergiyenko V.B. Yadernaya Kardiologiya = Nuclear Cardiology. Moscow, Natsional’nyy Meditsinskiy Issledovatel’skiy Tsentr Kardiologii Publ., 2021. 516 p. (In Russ.). ISBN 978-5-93856-283-7. EDN VFDVIL
10. Krivonogov N.G., Minin S.M., Krylov A.L., Lishmanov Yu.B. Quantitative Determination of Radionuclides in the Assessment of Myocardial Blood Flow. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2013;12;3:111–116 (In Russ.). EDN QZDKUF.
11. Usov V.Yu., Sukhov V.Yu., Babikov V.Yu., Borodin O.Yu., Vorozhtsova I.N., Lishmanov Yu.B., Udut V.V., Krivonogov N.G. Quantitative Spectral Measurement of Tissue Blood flow in the Myocardium by the Absolute Accumulation of the Radiopharmaceutical 99mTc-Technetril. Translyatsionnaya Meditsina = Translational Medicine. 2022;9;1:29–38 (In Russ.). Doi: 10.18705/2311-4495-2022-9-1-29-38.
12. Losev O.Ye., Borodulin V.B., Rusetskaya N.Yu., Bobyleva Ye.V., Borodulin Yu.V. Molecular Mechanisms of Lung Cancer. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya = Pathological Physiology and Experimental Therapy. 2021;65;1:124–132 (In Russ.). Doi: 10.25557/0031-2991.2021.01.124-132.
13. Korablev R.V., Vasil’yev A.G. Neoangiogenesis and Tumor Growth. Rossiyskiye Biomeditsinskiye Issledovaniya = Russian Biomedical Research. 2017;2;4:3-10 (In Russ.). EDN XSCZAT.
14. Kostyuchenko V.V. History of the Development of Stereotactic Radiation. Meditsinskaya Fizika = Medical Physics. 2015;4;68:85-97 (In Russ.). EDN VECGGF.
15. Kanayev S.V., Novikov S.N., Beynusov D.S., Levchenko Ye.V., Girshovich M.M., Zhukova L.A., Krzhivitskiy P.I. The Role of Single-Photon Emission Computed Tomography and X-Ray Computed Tomography in the Diagnosis of Metastatic Lesions of the Lymph Nodes in Patients with Non-Small Cell Lung Cancer. Radiatsionnaya Onkologiya i Yadernaya Meditsina = Nuclear and Radiation Safety Journal. 2013;1;2:47-52 (In Russ.). EDN TGOTZV.
16. Demeshko P.D., Sakovich R.A., Baranovskiy A.A., Sinayka V.V., Minaylo I.I., Merzlyakova A.K., Petkevich M.N. PET/CT in Planning Radiation Therapy for Non-Small Cell Lung Cancer. Onkologicheskiy Zhurnal = Oncological Journal. 2017;11;1:97–102 (In Russ.). EDN ZHNPRH.
17. Vorob’yeva V.O., Nudnov N.V., Miller S.V., Rodionov Ye.V., Usov V.Yu. Magnetic Resonance Imaging of the Lungs with Paramagnetic Contrast Enhancement in the Dynamic Control of Lung Cancer Treatment in a Radiophobic Patient: a Clinical Observation. Luchevaya Diagnostika i Luchevaya Terapiya = Diagnostic Radiology and Radiotherapy. 2022;13;3:97–107 (In Russ.). Doi: http://dx.doi.org/10.22328/2079-5343-2022-13-3-97-107.
18. Tyurin I.Ye. Radiation Diagnostics in the Russian Federation. Onkologicheskiy Zhurnal = Oncological Journal. 2018;1;4:43-51 (In Russ.). EDN QZSWYK.
19. Sorokina K.N., Tulupov A.A., Tolstikova T.G., Usov V.Yu. Modern Approaches to the Development of Contrast Agents for MRI Diagnostics. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2011;10;6:79-85 (In Russ.). EDN ONZEDZ.
20. Usov V.YU., Ryannel’ YU.Ye., Mikhaylovich YA.M., Slonimskaya Ye.M., Velichko S.A. Mammascintigraphy: Basics, Protocols, and Clinical Application. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 1999;44;3:72-82 (In Russ.). EDN MPDAQN.
21. Khafizov M.M., Baykov D.E., Akhmadeyeva L.R. Radioisotope Visualization of Mediastinal Forms of B-cell Lymphoma and Differential Diagnosis of Pathologically Altered Areas of Adjacent Lung Parenchyma Using PET/CT with 18F-FDG and SPECT/CT with 99mTc-MIBI. Effektivnaya Farmakoterapiya = Effective Pharmacotherapy. 2023;19;48:30-33 (In Russ.). Doi: 10.33978/2307-3586-2023-19-48-30-33. EDN DYMBLN.
22. Minin S.M., Anashbayev Zh.Zh., Novikova N.V., Samoylova Ye.A., Sazonova S.I., Salin N.V., Korobeynikov S.M., Usov V.Yu., Chernyavskiy A.M. Possibilities of Using Single-Photon Emission Computed Tomography (SPECT-CT) with 99mTc-Technetrile in Screening of Chest Tumors (Lung Cancer, Breast Cancer) in Patients with Cardiovascular Pathology. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2025;70;6:45-54 (In Russ.). Doi: 10.33266/1024-6177-2023-68-5-96-104.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-49-56
S.G. Mikhaylov1, A.V. Perfiliev2, N.V. Yukhimenko1
Opportunities of Radionuclide Diagnostics
with 99mТc-MIBI in Children with Tuberculosis
1 Central Tuberculosis Research Institute, Moscow, Russia
2 M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russia
Contact person: S.G. Mikhaylov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Study the informativeness of radionuclide diagnostics with 99mTc-MIBI in determining the prevalence and activity of the inflammatory process in children with tuberculosis.
Material and methods: The examinations were conducted with the written consent of the patients’ parents. 28 children aged 3 to 13 years were examined. Among the subjects there were 12 boys (43.0 %), 16 girls (57.0 %). Among the clinical forms in children, the following predominated: tuberculosis of the intrathoracic lymph nodes – 11 children (39.3 %) and focal tuberculosis – 11 children (39.3 %), the Ghon focus – 3 children (10.7 %), primary tuberculosis complex – 2 children (7.1 %), tuberculosis of multiple localization – 1 child. To assess the activity of the specific process in the lungs and intrathoracic lymph nodes, a comprehensive clinical and laboratory examination was carried out taking into account the results of skin immunological tests. All children underwent chest computed tomography (CT) and 99mTc-MIBI SPECT.
Results: The use of SPECT with 99mTc-MIBI in pediatric phthisiology allows for reliable determination of the activity and prevalence of the tuberculosis process in the lungs and mediastinal lymph nodes. The sensitivity of the radioisotope method with 99mTc-MIBI in detecting active inflammatory changes in the lungs and mediastinal lymph nodes was 82.1 % in our study. The significance of radionuclide research with 99mTc-MIBI for choosing tactics and determining the effectiveness of anti-tuberculosis chemotherapy in children was established, taking into account the degree of accumulation of the radiopharmaceutical in the pathological focus.
Keywords: 99mTc-MIBI, SPECT, children, tuberculosis
For citation: Mikhaylov SG, Perfiliev AV, Yukhimenko NV. Opportunities of Radionuclide Diagnostics with 99mТc-MIBI in Children with Tuberculosis. Medical Radiology and Radiation Safety. 2026;71(1):49–56. (In Russian). DOI:10.33266/1024-6177-2026-71-1-49-56
References
1. Gubkina M.F., Khokhlova Yu.Yu., Petrakova I.Yu., Yukhimenko N.V., Sterlikova S.S. Clinical and Radiological Characteristics of Tuberculosis of the Respiratory Organs in Children from Foci of Tuberculosis Infection with Different Results of Microbiological Examination of Sputum at the Source of Infection. Vestnik Tsentral’nogo Nauchno-Issledovatel’skogo Instituta Tuberkuleza = Bulletin of the Central Research Institute of Tuberculosis. 2021;3:36-42 (In Russ.).
2. Plekhanova M.A., Aksenova V.A., Krivtsova L.A. Personalized Early Diagnosis and Prognosis of the Course of Tuberculosis Infection in Children with the Identification of Predictors of Latent Tuberculosis Infection and Tuberculosis. Tuberkuloz i Bolezni Logkikh = Tuberculosis and Lung Diseases. 2021;99;1:33-39 (In Russ.). Doi: 10.21292/2075-1230-2021-99-1-33-39.
3. Perfil’yev A.V., Sigayev A.T. Lung Scintigraphy with 67Ga-Citrate, 201Tl-Chloride and 99mTc-Technetrile in Patients with Pulmonary Tuberculosis. Tuberkulez Segodnya: Problemy i Perspektivy = Tuberculosis Today: Problems and Prospects. Moscow, Moskovskiy Gorodskoy Nauchno-Prakticheskiy Tsentr Bor’by s Tuberkulezom Publ., 2000. P. 153-154 (In Russ.).
4. Sigayev A.T., Chukanov V.I., Perfil’yev A.V. The Role of Radionuclide Research Methods in Assessing the Activity of the Pathological Process in the Lymph Nodes and Lungs in Patients with Tuberculosis. Problemy Tuberkuleza i Bolezney Legkikh = Problems of Tuberculosis and Lung Diseases. 2004;8:50 (In Russ.).
5. Tlostanova M.S., Popova Ye.A., Avetisyan A.O., Blyum N.M., Kozak A.R., Petrun’kin A.M. Possibilities of Positron Emission Tomography with 18F-Fluorodeoxyglucose and 11C-Methionine in Determining the Activity of Pulmonary Tuberculosis: Metabolic and Morphological Parallels. Sovremennyye Tekhnologii v Meditsine = Modern Technologies in Medicine. 2014;6;4:78-84 (In Russ.).
6. Onsel C., Sönmezoglu K., Camsari G., Atay S., Cetin S., Erdil Y.T., Uslu I., Uzun A., Kanmaz B., Sayman H.B. Technetium-99m-MIBI Scintigraphy in Pulmonary Tuberculosis. J Nucl Med. 1996;37;2:233-238.
7. Raziei G., Masjedi M.R., Fotouhi F., Asli N.I., Shafiei B., Javadi H., Assadi M. The Role of 99mTc-MIBI Scintigraphy in the Management of Patients with Pulmonary Tuberculosis. Eur Rev Med Pharmacol Sci. 2012;16;5:622-629.
8. Kanayev S.V., Novikov S.N., Beynusov D.S., Girshovich M.M., Levchenko Ye.V., et al. Experience in Using Simultaneous Dual-Isotope Emission Computed Tomography with 99mTc-Technetrile and 67Ga-citrate in Examining Patients with Non-Small Cell Lung Cancer. Voprosy Onkologii = Problems in Oncology. 2012;3:346-351 (In Russ.).
9. Shiryayev S.V. Diagnostic Use of Radiopharmaceuticals Based on Tc-99m in Oncology: Present and Future. Yadernaya Meditsina v XXI Veke: Klinicheskiye i Metodicheskiye Aspekty Ispol’zovaniya Radiofarmatsevticheskikh Preparatov na Osnove Tc-99m = Nuclear Medicine in the 21st Century: Clinical and Methodological Aspects of the Use of Radiopharmaceuticals Based on Tc-99m. Abstracts of Reports. Dubna Publ., 2002. P. 13–16 (In Russ.).
10. Guoliang Xia, Chuanguo An, Zonghua Ming, Hong Guo, Lihong Liu, Yufeng Li. 18F-FDG-PET/CT Versus 99mTc-MIBI-SPECT. Which is Better for Detection of Solitary Pulmonary Nodules? JBUON. 2017;22;5:1246-1251.
11. Kao C.H., Chang Lai S.P., Chieng P.U., Yen T.C. Technetium-99m Methoxyisobutylisonitrile Chest Imaging of Small Cell Lung Carcinoma: Relation to Patient Prognosis and Chemotherapy Response-a Preliminary Report. Cancer. 1998;83;1:64-68.
12. Tuberkulez Organov Dykhaniya = Tuberculosis of the Respiratory Organs. Ed. A.G.Khomenko. Handbook for Physicians. Moscow, Meditsina Publ., 1988. 575 p. (In Russ.). ISBN 5-225-00049-5.
13. Sigayev A.T., Chukanov V.I., Perfil’yev A.V. The Role of Radionuclide Research Methods in Assessing the Activity of the Pathological Process in the Lymph Nodes and Lungs in Patients with Tuberculosis. Problemy Tuberkuleza i Bolezney Legkikh = Problems of Tuberculosis and Lung Diseases. 2004;8:50-53 (In Russ.).
14. Perfil’yev A.V., Ergeshov A.E., Demikhova O.V., Sigayev A.T., Klimov G.V., Amansakhedov R.B., Mikhaylov S.G. Possibilities of Radionuclide Diagnostics in Staging the Severity of Tuberculous Inflammation in Patients with HIV Infection. Tuberkulez i Sotsial’no-Znachimyye Zabolevaniya = Tuberculosis and Socially Significant Diseases. 2015;6:112-113
(In Russ.).
15. Amansakhedov R.B., Gubkina M.F., Mikhaylov S.G., Perfil’yev A.V., Yukhimenko N.V. Sposob Diagnostiki Vyrazhennosti i Rasprostranennosti Vospalitel’nogo Protsessa u Bol’nykh Tuberkulezom Detey = Method for Diagnosing the Severity and Prevalence of the Inflammatory Process in Children with Tuberculosis. Patent No. RU 2 823 857 C2, 2024. Applicant: Central Research Institute of Tuberculosis (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out as part of the research project ‟New Approaches to the Diagnosis and Treatment of Respiratory Tuberculosis in Children and Adolescents” at the Central Research Institute of Tuberculosis.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-67-72
V.K. Tishchenko1, A.V. Fedorova1, O.F. Chibisova1, N.B. Morozova2,
A.A. Lebedeva1, S.P. Orlenko1, A.A. Solyanov1, A.A. Ostroukhov1,
O.P. Vlasova1, 3, A.D. Kaprin2, 3, 4
Biological Distribution of Radioconjugates Based
on Somatostatin Analogs and Radionuclide Actinium-225
1 A.F. Tsyb Medical Radiological Research Centre, Obninsk, Russia
2 P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
3 National Medical Research Radiological Centre, Obninsk, Russia
4 Рeoples Friendship University of Russia, Moscow, Russia
Contact person: Viktoriia Konstantinovna Tishchenko, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Comparative studies of metal complexes 225Ac-DOTA-TOC and 225Ac-DOTA-TATE biodistribution in laboratory animals with an experimental model of malignant tumor and optimal radioconjugate determination for further preclinical studies.
Material and methods: Radiochemical synthesis of 225Ac-DOTA-TOC and 225Ac-DOTA-TATE metal complexes was carried out using chemical precursors DOTA-TOC and DOTA-TATE in lyophilic form (JSC Pharm-Sintez) and actinium-225 chloride (IPPE JSC). Biodistribution studies were performed in immunodeficient NU/J mice, females, with subcutaneously transplanted SK-Mel-28 melanoma. Biodistribution of radiopharmaceuticals was assessed ex vivo and measured by the radiometric method with an automatic gamma counter by the specific activity in samples of organs and tissues measurement.
Results: Radioconjugates 225Ac-DOTA-TOC and 225Ac-DOTA-TATE had similar biodistribution in tumor-bearing animals after a single intravenous administration. The highest accumulation of both radioconjugates was observed in the kidneys: 8.908–45.243 %ID/g and 3.816–25.694 %ID/g for 225Ac-DOTA-TOC and 225Ac-DOTA-TATE, respectively. The uptake of 225Ac-DOTA-TATE (0.179–3.869 %ID/g) in tumor was higher than 225Ac-DOTA-TOC (0.120–1.514 %ID/g), however, statistically significant differences (p < 0.05) were observed only at 5 min after administration. There were not statistically significant differences between the uptake of 225Ac-DOTA-TOC and 225Ac-DOTA-TATE in other organs and tissues. Analysis of tumor/organs values showed that the concentration of 225Ac-DOTA-TOC and 225Ac-DOTA-TATE in tumor was higher than in most organs, except liver and kidneys. The lowest uptake of both radiopharmaceuticals was registered in the brain (less than 0.1 %ID/g).
Conclusion: According to the results of this study, the radioconjugate 225Ac-DOTA-TATE has optimal biodistribution (higher accumulation in the tumor and lower in the kidneys as compared with 225Ac-DOTA-TOC), so 225Ac-DOTA-TATE was chosen for further preclinical studies.
Keywords: radiopharmaceuticals, actinium-225, somatostatin analogs, DOTA-TOC, DOTA-TATE, biodistribution, mice
For citation: Tishchenko VK, Fedorova AV, Chibisova OF, Morozova NB, Lebedeva AA, Orlenko SP, Solyanov AA, Ostroukhov AA, Vlasova OP, Kaprin AD. Biological Distribution of Radioconjugates Based on Somatostatin Analogs and Radionuclide Actinium-225. Medical Radiology and Radiation Safety. 2026;71(1):67–72. (In Russian). DOI:10.33266/1024-6177-2026-71-1-67-72
References
1. Sultana Q., Kar J., Verma A., Sanghvi S., Kaka N., Patel N., Sethi Y., Chopra H., Kamal M.A., Greig N.H. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. J. Clin. Med. 2023;12;15:5138. Doi: 10.3390/jcm12155138.
2. Тищенко В.К., Петриев В.М., Крылов В.В., Власова О.П., Шегай П.В., Иванов С.А., Каприн А.Д. Аналоги соматостатина, меченные радионуклидами, для терапии онкологических заболеваний (обзор) // Радиация и риск (Бюллетень Национального радиационно-эпидемиологического регистра). 2022. Т.31. №2. С. 76-96. [Tishchenko V.K., Petriyev V.M., Krylov V.V., Vlasova O.P., Shegay P.V., Ivanov S.A., Kaprin A.D. Radionuclide-Labeled Somatostatin Analogues for Cancer Therapy (Review). Radiatsiya i Risk (Byulleten’ Natsional’nogo Radiatsionno-Epidemiologicheskogo Registra) = Radiation and Risk. 2022;31;2:76-96 (In Russ.)]. Doi: 10.21870/0131-3878-2022-31-2-76-96.
3. Hennrich U., Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel). 2019;12;3:114. Doi: 10.3390/ph12030114.
4. Di Franco M., Lamberti G., Campana D., Ambrosini V. Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET). Semin. Nucl. Med. 2025;S0001-2998;25:00049-2. Doi: 10.1053/j.semnuclmed.2025.04.005.
5. Zhao J., Pei X., Li Y. Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. Cureus. 2025;17;3:e80817. Doi: 10.7759/cureus.80817.
6. Rubira L., Deshayes E., Santoro L., Kotzki P.O., Fersing C. 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: from Radiochemistry to Clinic. Pharmaceutics. 2023;15;4:1051. Doi: 10.3390/pharmaceutics15041051.
7. Miederer M., Henriksen G., Alke A., Mossbrugger I., Quintanilla-Martinez L., Senekowitsch-Schmidtke R., Essler M. Preclinical Evaluation of the Alpha-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors. Clin. Cancer Res. 2008;14;11:3555–61. Doi: 10.1158/1078-0432.CCR-07-4647.
8. Chan H.S., Konijnenberg M.W., de Blois E., Koelewijn S., Baum R.P., Morgenstern A., Bruchertseifer F., Breeman W.A., de Jong M. Influence of Tumour Size on the Efficacy of Targeted Alpha Therapy with 213Bi-[DOTA(0),Tyr(3)]-Octreotate. EJNMMI Res. 2016;6;1:6. Doi: 10.1186/s13550-016-0162-2.
9. Lee D., Li M., Liu D., Baumhover N.J., Sagastume E.A., Marks B.M., Rastogi P., Pigge F.C., Menda Y., Johnson F.L., Schultz M.K. Structural Modifications Toward Improved Lead-203/Lead-212 Peptide-Based Image-Guided Alpha-Particle Radiopharmaceutical Therapies for Neuroendocrine Tumors. Eur. J. Nucl. Med. Mol. Imaging. 2024;51;4:1147–1162. Doi: 10.1007/s00259-023-06494-9.
10. Zhang J., Kulkarni H.R., Baum R.P. 225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation. Clin. Nucl. Med. 2021;46;12:1030–1031. Doi: 10.1097/RLU.0000000000003792.
11. Kratochwil C., Apostolidis L., Rathke H., Apostolidis C., Bicu F., Bruchertseifer F., Choyke P.L., Haberkorn U., Giesel F.L., Morgenstern A. Dosing 225Ac-DOTATOC in Patients with Somatostatin-Receptor-Positive Solid Tumors: 5-year Follow-Up of Hematological and Renal Toxicity. Eur. J. Nucl. Med. Mol. Imaging. 2021;49;1:54–63. Doi: 10.1007/s00259-021-05474-1.
12. Ballal S., Yadav M.P., Bal C., Sahoo R.K., Tripathi M. Broadening Horizons with 225Ac-DOTATATE Targeted Alpha Therapy for Gastroenteropancreatic Neuroendocrine Tumour Patients Stable or Refractory to 177Lu-DOTATATE PRRT: First Clinical Experience on the Efficacy and Safety. Eur. J. Nucl. Med. Mol. Imaging. 2020;47;4:934–946. Doi: 10.1007/s00259-019-04567-2.
13. Demirci E., Selçuk N.A., Beydaği G., Ocak M., Toklu T., Akçay K., Kabasakal L. Initial Findings on the Use of [225Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors. Mol. Imaging Radionucl. Ther. 2023;32;3:226–232. Doi: 10.4274/mirt.galenos.2023.38258.
14. Тищенко В.К., Вирясов М.Б., Рыжикова Т.П., Степченкова Е.Д., Остроухов А.А., Щербакова А.Н., Дороватовский С.А., Власова О.П., Иванов С.А. Лабораторный синтез металлокомплексов радионуклида актиния-225 с пептидными молекулами – аналогами соматостатина для радионуклидной терапии нейроэндокринных опухолей // Химико-фармацевтический журнал. 2025. Т.59. №3. С. 39–44 [Tishchenko V.K., Viryasov M.B., Ryzhikova T.P., Stepchenkova Ye.D., Ostroukhov A.A., Shcherbakova A.N., Dorovatovskiy S.A., Vlasova O.P., Ivanov S.A. Laboratory Synthesis of Metal Complexes of Actinium-225 Radionuclide with Peptide Molecules - Analogues of Somatostatin for Radionuclide Therapy of Neuroendocrine Tumors. Khimiko-Farmatsevticheskiy Zhurnal = Chemical-Pharmaceutical Journal. 2025;59;3:335–340 (In Russ.)]. Doi: 10.30906/0023-1134-2025-59-3-39-44.
15. Wijaya R.R., Budiawan H., Hidayat B., Darmawan B., Nugrahadi T., Kartamihardja A.H.S. Comparison of Radiolabeled Somatostatin Analogs (DOTATATE, DOTANOC, and DOTATOC) in Somatostatin Receptor (SSTR) Imaging for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): a Narrative Literature Review. Ann. Nucl. Med. 2025 Aug;39;8:755-773. Doi: 10.1007/s12149-025-02072-1.
16. Massironi S., Albertelli M., Hasballa I., Paravani P., Ferone D., Faggiano A., Danese S. “Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy. Cells. 2025;14;4:245. Doi: 10.3390/cells14040245.
17. Günter T., Tulipano G., Dournaud P., Bousquet C., Csaba Z., Kreienkamp H.J., Lupp A., Korbonits M., Castaño J.P., Wester H.J., Culler M., Melmed S., Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev. 2018;70;4:763–835. Doi: 10.1124/pr.117.015388.
18. Erbas B., Tuncel M. Renal Function Assessment during Peptide Receptor Radionuclide Therapy. Semin. Nucl. Med. 2016;46;5:462–478. Doi: 10.1053/j.semnuclmed.2016.04.006.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The research was carried out with the financial support of Ministry of Health of the Russian Federation within implementation of state assignment № 124030500022-1.
Contribution. A.D. Kaprin aided in the concept and plan of the study; V.K. Tishchenko, O.P. Vlasova provided collection and analysis of data; preparation of the manuscript – V.K. Tishchenko, O.P. Vlasova.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.